Community-acquired pneumonia (CAP) is a common cause of morbidity and mortality and is associated with the consumption … azithromycin is not recommended for use (presumably as monotherapy) in patients with moderate to severe pneumonia, bacteraemia or …

In patients with community-acquired pneumonia (CAP), it is uncommon for the causative pathogen to be identified when … which covers the major pathogens of CAP. Although Streptococcus pneumoniae remains the most common pathogen in … alternative therapy for penicillin-susceptible S. pneumoniae or M. catarrhalis infection. Clarithromycin has good in vitro …

utilisation included costs for study antibacterials, treatment of adverse effects and failures, and hospitalisation. The primary …

antibacterials in the management of ABECB, and the factors that may affect the cost-effectiveness of antibacterials in the management … follows: 1. a key factor affecting the cost-effective use of antibacterials in the management of ABECB is the definitive … ensuring that antibacterials are not prescribed unnecessarily; 2. current evidence suggests but does not prove that use of more …

Community-acquired pneumonia (CAP) infects upwards of four million people in the US each year, of which 20% require … causes, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and the atypical pathogens (Mycoplasma … pneumoniae, Chlamydia pneumoniae and Legionella pneumophila). A variety of pharmaceutical agents exist for the treatment of CAP …

-acquired pneumonia. Piperacillin/tazobactam plus amikacin had lower total costs than ceftazidime plus amikacin in another cost analysis … tobramycin was more costly than ceftazidime plus tobramycin in hospital-acquired pneumonia in a US cost analysis. In cost …-effectiveness analyses, all studies of intra-abdominal infections, pneumonia and febrile neutropenic episodes consistently reported lower …